- Home
- RPTX vs ADAG Comparison
RPTX vs ADAG Comparison
Compare RPTX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- ADAG
- Stock Information
- Founded
- RPTX 2016
- ADAG 2011
- Country
- RPTX Canada
- ADAG China
- Employees
- RPTX N/A
- ADAG 174
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- ADAG Health Care
- Exchange
- RPTX Nasdaq
- ADAG Nasdaq
- Market Cap
- RPTX 119.7M
- ADAG 100.5M
- IPO Year
- RPTX 2020
- ADAG 2021
- Fundamental
- Price
- RPTX $3.75
- ADAG $2.21
- Analyst Decision
- RPTX Strong Buy
- ADAG Strong Buy
- Analyst Count
- RPTX 3
- ADAG 1
- Target Price
- RPTX $17.33
- ADAG $5.00
- AVG Volume (30 Days)
- RPTX 147.3K
- ADAG 94.6K
- Earning Date
- RPTX 11-07-2024
- ADAG 07-25-2024
- Dividend Yield
- RPTX N/A
- ADAG N/A
- EPS Growth
- RPTX N/A
- ADAG N/A
- EPS
- RPTX N/A
- ADAG N/A
- Revenue
- RPTX $68,683,000.00
- ADAG $815,746.00
- Revenue This Year
- RPTX $16.85
- ADAG N/A
- Revenue Next Year
- RPTX N/A
- ADAG $2.70
- P/E Ratio
- RPTX N/A
- ADAG N/A
- Revenue Growth
- RPTX N/A
- ADAG N/A
- 52 Week Low
- RPTX $2.71
- ADAG $1.30
- 52 Week High
- RPTX $8.49
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- RPTX 68.01
- ADAG 42.53
- Support Level
- RPTX $3.37
- ADAG $2.10
- Resistance Level
- RPTX $3.72
- ADAG $2.41
- Average True Range (ATR)
- RPTX 0.19
- ADAG 0.30
- MACD
- RPTX 0.03
- ADAG -0.02
- Stochastic Oscillator
- RPTX 85.60
- ADAG 37.27
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.